Therefore, T-ALL patients showing upregulation of AUTS2 or MSX1 may benefit from treatments with specific inhibitors of chromatin regulators, representing a promising therapeutic approach for this subset of patients. Here, MSX1 is linked to acute lymphoblastic leukemia.